Opinion|Videos|June 14, 2024
Assessing Limitations, Costs, Mobility and Cognition in Progressive Multiple Sclerosis
Heidi Crayton, MD, and Maria Lopes, MD, discuss the limitations of using relapse rates as a critical endpoint in trials for patients with non-relapsing secondary progressive multiple sclerosis experiencing disease progression without relapse, explore methods to assess therapeutic benefit in this population, examine the relationship between cost of care and disease severity, and highlight the impact of decreased mobility and cognition on MS patients along with strategies for improvement.
Advertisement
Episodes in this series
- Relapse rates have traditionally been viewed as a critical endpoint for previous MS trials, which are not applicable in patients with non-relapsing secondary progressive multiple sclerosis with disease progression without relapse. How do you determine whether a patient is benefitting from therapy in this patient population?
- What is the relationship of costs of
care and disease severity in patients with MS, and how do payers view the current costs of care for patients with MS? - What is the impact of decreased mobility and cognition on patients with MS, and what are some strategies to help improve it?
Advertisement
Related to this article
The Autus Size-Adjustable Valve, which can be expanded as children grow, may reduce the need for repeat open-heart surgeries for congenital defects.
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.
Invivyd's VYD2311 shows superior safety and tolerability vs Comirnaty in the phase 3 LIBERTY trial, with no vaccine interference.
Survodutide achieved up to 13.1% weight loss vs 3.1% with placebo at 76 weeks in adults with obesity and T2D in the phase 3 SYNCHRONIZE-2 trial.
A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.
Weekend catch-up sleep was associated with lower odds of overactive bladder and milder symptoms, with the benefit concentrated in the first 1.5 hours.
Advertisement
Advertisement
Trending on AJMC
1
Perspectives on Health-Related Social Needs for Medicare Advantage Beneficiaries
2
Systemic Sclerosis Linked to Dramatic Rise in Lung Cancer Risk
3
FDA Approves First Heart Valve to Keep Pace With Children's Growth
4
Psoriasis Is Much Rarer in Indigenous Groups Worldwide
5